Clinical benefit of adding radiation for immune checkpoint inhibitor-refractory Merkel cell carcinoma: A 27-patient analysis | Synapse
March 3, 2026
Clinical benefit of adding radiation for immune checkpoint inhibitor-refractory Merkel cell carcinoma: A 27-patient analysis
Puntos clave
Radiation therapy improves tumor response in patients with Merkel cell carcinoma that has resisted immune checkpoint inhibitors, indicating a new avenue for care.
The clinical outcomes show that 27 patients benefited from the combined treatment approach, revealing promising results.
Observational analysis involved assessing clinical outcomes after radiation was added to traditional immune checkpoint inhibitor therapy.
Highlights a potential shift in treatment for difficult-to-treat Merkel cell carcinoma cases, needing further validation.